Pharmaceutical

UK MHRA approves new formulation of Amgen’s XGEVA

The UK MHRA has granted marketing authorisation for a new formulation of Amgen’s XGEVA to prevent serious bone-related complications.

Mar 1, 2024 - 18:00
UK MHRA approves new formulation of Amgen’s XGEVA
The UK MHRA has granted marketing authorisation for a new formulation of Amgen’s XGEVA to prevent serious bone-related complications.
Read the original article

Tags:

Previous Article

1910 Genetics and Microsoft partner to enhance pharmaceutical R&D

Next Article

Simtra BioPharma to invest more than $250m in US facility

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

BioNTech and DualityBio team up to develop ADC therapeutics for cancer

BioNTech and DualityBio team up to develop ADC therapeu...

Apr 3, 2023

Flu vaccine offering decent levels of protection this winter, new data show

Flu vaccine offering decent levels of protection this w...

Feb 29, 2024

STAT+: FDA advisory panel recommends conditional approval of Biogen’s drug for rare form of ALS

STAT+: FDA advisory panel recommends conditional approv...

Mar 22, 2023